Wegovy Oral Medication Breakthrough: FDA Review Signals New Era in Weight Loss Treatment and Obesity Management
Failed to add items
Sorry, we are unable to add the item because your shopping cart is already at capacity.
Add to Cart failed.
Please try again later
Add to Wish List failed.
Please try again later
Remove from wishlist failed.
Please try again later
Adding to library failed
Please try again
Follow podcast failed
Please try again
Unfollow podcast failed
Please try again
Wegovy Oral Medication Breakthrough: FDA Review Signals New Era in Weight Loss Treatment and Obesity Management
-
Narrated by:
-
By:
About this listen
Discover the groundbreaking developments in the weight loss medication landscape as host Alexandra Reeves dives deep into Novo Nordisk's Wegovy. This episode unpacks the FDA's recent action date for an innovative oral formulation of Wegovy that could revolutionize obesity treatment, potentially becoming the first oral GLP-1 drug for chronic weight management.
Learn about the major market shift as CVS Caremark names Wegovy its preferred GLP-1 treatment for obesity, effectively reshaping competition in the pharmaceutical industry. The podcast explores how this decision impacted Eli Lilly's stock and what it means for patients currently using competing medications.
Alexandra also examines Novo Nordisk's strategic moves to improve medication accessibility, including their launch of NovoCare Pharmacy offering reduced costs for self-paying patients and expanded telehealth collaborations. Get insights into the medication's potential side effects, approval history, and the fascinating origin story behind Novo Nordisk itself.
Perfect for healthcare professionals, individuals managing weight issues, or anyone interested in pharmaceutical innovations, this episode provides crucial context for understanding how these developments will shape the future of obesity treatment.
adbl_web_global_use_to_activate_T1_webcro805_stickypopup
No reviews yet